Addyi Hair and Skin Changes: What the Evidence Actually Shows

What Is Flibanserin and Why Does Skin Matter?

Flibanserin acts on central serotonin and dopamine receptors rather than sex-hormone pathways, which matters for understanding its dermatologic profile. Unlike spironolactone or finasteride, two drugs used for both HSDD-adjacent conditions and hair loss, flibanserin has no known anti-androgenic activity. That distinction shapes the entire conversation about hair and skin.

The drug was developed by Boehringer Ingelheim and later acquired by Sprout Pharmaceuticals before the current rights holder, Cosmo Pharmaceuticals. Its FDA approval followed two complete response letters and a substantial clinical review of more than 11,000 patient-years of exposure across the Phase 2 and Phase 3 programs [1].

The Receptor Profile and Skin Biology

Serotonin signaling is biologically active in the skin. Keratinocytes, melanocytes, and dermal fibroblasts all express serotonin receptors, and 5-HT1A agonism has been studied in wound-healing models [2]. Whether those in-vitro observations translate to any clinically meaningful skin effect at the 100 mg nightly dose used clinically remains unproven. No Phase 3 trial of flibanserin was designed to capture dermatologic endpoints systematically.

Hormonal Drugs vs. Flibanserin: A Key Distinction

Many patients searching "Addyi hair and skin changes" are actually concerned about the hormonal therapies sometimes prescribed alongside HSDD treatment, including combined oral contraceptives, testosterone gels, or estradiol. Those agents have well-documented effects on sebum production, acne, and androgenetic alopecia. Flibanserin itself is not hormonal. Confirming which agent is causing a dermatologic symptom requires a careful medication reconciliation.

The BEGONIA Trial: Primary Evidence on Adverse Events

BEGONIA (published in the Journal of Sexual Medicine, 2014) enrolled 949 premenopausal women with HSDD and randomized them to flibanserin 100 mg at bedtime or placebo for 24 weeks [3]. The trial is the most-cited Phase 3 dataset for this indication and is frequently referenced in FDA review documents.

What BEGONIA Found on Efficacy

Flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks, with a least-squares mean difference of approximately 0.5 SSEs per 28 days (P<0.05) [3]. The Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire also showed significant improvement. Effect sizes were modest by conventional standards, a point the FDA's own medical review acknowledged.

BEGONIA Adverse-Event Data Relevant to Skin and Hair

The BEGONIA adverse-event table identified the following treatment-emergent findings at a frequency greater than 2% and higher than placebo: somnolence (11.4% vs. 4.0%), dizziness (10.6% vs. 3.5%), nausea (9.2% vs. 4.7%), and fatigue (7.7% vs. 3.3%) [3]. Rash appeared in the broader pooled safety dataset but was not reported as a distinguishing signal in BEGONIA specifically. Alopecia did not appear in the published adverse-event tables.

Pooled Phase 3 Safety Program

The FDA's August 2015 drug approval package summarized safety data across five Phase 3 trials involving more than 2,000 women receiving flibanserin and roughly 1,500 receiving placebo [1]. Discontinuation due to adverse events occurred in 13% of flibanserin patients versus 6% of placebo patients, driven primarily by CNS and hypotensive effects. Dermatologic adverse events were not among the top reasons for discontinuation in any of the five trials.

Hair Loss and Flibanserin: Separating Signal from Noise

No Phase 3 trial has identified drug-induced alopecia as a treatment-emergent adverse event for flibanserin. That absence is meaningful, but it is not the full story.

Post-Marketing Reports

The FDA Adverse Event Reporting System (FAERS) receives voluntary reports of suspected drug reactions after approval. A search of published FAERS analyses through 2024 does not surface a concentrated alopecia signal for flibanserin comparable to, for example, the documented hair-loss reports associated with GLP-1 receptor agonists (where telogen effluvium secondary to rapid weight loss is the proposed mechanism) [4]. Because flibanserin does not cause significant weight change, that particular pathway does not apply.

Why Some Patients Report Hair Changes

Several factors may explain individual patient reports of hair changes during flibanserin therapy. First, coincident timing is common: HSDD itself often co-occurs with perimenopause, a period of androgenetic change affecting hair density independently. Second, stress-related telogen effluvium can emerge months after a physiologic stressor, creating a temporal association with a newly started medication that is actually incidental. Third, if a patient starts flibanserin alongside a hormonal agent, the hormonal agent is the more plausible culprit.

Serotonergic Drugs and Hair: The Broader Literature

Selective serotonin reuptake inhibitors (SSRIs) have a documented, though uncommon, association with telogen effluvium, estimated at roughly 1 in 1,000 treated patients in a retrospective pharmacovigilance analysis [5]. Flibanserin is not an SSRI, but it does share 5-HT receptor activity. Whether that mechanistic overlap confers any finite alopecia risk at the 100 mg nightly dose has not been studied in a dedicated trial.

Clinical Decision Framework: Evaluating New Hair Loss in a Patient on Flibanserin

1. Confirm the timeline: did hair shedding begin within 2 to 4 months of starting flibanserin, or does it predate the prescription?
2. Review the full medication list for concurrent hormonal, antifungal, or anticoagulant agents with known alopecia associations.
3. Order TSH, ferritin, CBC, and a comprehensive metabolic panel. Telogen effluvium is frequently driven by nutritional or thyroid factors unrelated to any drug.
4. If flibanserin is the only plausible candidate and symptom severity warrants it, a 12-week trial off the drug (with documentation of HSDD symptom rebound) may clarify causality.
5. Refer to dermatology for a pull test and, if indicated, scalp biopsy before attributing alopecia to any specific agent.

Skin Findings in the Clinical Trial Program

The labeled prescribing information for Addyi lists the following adverse reactions occurring at greater than or equal to 2% incidence and at a rate at least twice that of placebo: dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth [1]. Rash is mentioned in the postmarketing section of the prescribing information without a frequency estimate, which means it was identified after FDA approval from spontaneous reports rather than from controlled trial data.

Flushing and Vasomotor Skin Effects

Flushing, defined as transient facial or truncal erythema, occurs in some patients. This is consistent with the drug's dopaminergic activity and its potential to cause peripheral vasodilation at higher plasma concentrations. The interaction with alcohol dramatically amplifies this effect, which is part of the reason the Addyi REMS program (Risk Evaluation and Mitigation Strategy) originally required a certified prescriber program [1]. That REMS program was later modified after a post-marketing study, but the alcohol interaction warning remains in the label.

Contact or Allergic Reactions

No specific excipient in the flibanserin tablet formulation has been flagged as a dermatologic sensitizer in the published literature. The tablet contains microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, hypromellose, and magnesium stearate [1]. Patients with documented lactose intolerance or hypersensitivity to cellulose-based excipients should review the full inactive ingredient list with their pharmacist.

Photodermatitis and Sun Sensitivity

The current prescribing information does not list photosensitivity as an adverse reaction. No Phase 3 trial reported photodermatitis as a treatment-emergent event. Patients do not need to take special sun-avoidance precautions specifically because of flibanserin.

Comparing Flibanserin to Other HSDD-Adjacent Treatments on Hair and Skin

Understanding how flibanserin compares to other agents used in or around HSDD management helps put the dermatologic risk profile in context.

Bremelanotide (Vyleesi)

Bremelanotide is a melanocortin receptor agonist approved for HSDD in premenopausal women in 2019. Because it acts on melanocortin receptors (MC1R, MC3R, MC4R), it carries a labeled warning for transient focal hyperpigmentation, particularly of the face, gums, and breasts, after repeated dosing [6]. The mechanism involves MC1R stimulation driving melanogenesis in keratinocytes. Flibanserin has no melanocortin activity and carries no comparable hyperpigmentation warning. This distinction matters when counseling patients who are choosing between the two approved options.

Testosterone Therapy (Off-Label)

Exogenous testosterone used off-label for HSDD can cause acne vulgaris and, at supraphysiologic levels, androgenetic alopecia. The Endocrine Society's 2014 clinical practice guideline on androgen therapy in women notes that testosterone formulations approved for men carry particular risks of virilization, including acne and hair changes, when used at typical male doses in women [7]. Flibanserin carries none of those androgenic risks.

SSRIs (as a Conceptual Comparator)

SSRIs are sometimes prescribed for comorbid depression in women with HSDD, and paroxetine specifically has a low-level association with hair thinning in post-marketing reports. The FDA label for flibanserin warns against combined use with fluoxetine and other strong or moderate CYP2C19 or CYP3A4 inhibitors, because those interactions raise flibanserin plasma concentrations several-fold and increase adverse effects [1]. If a patient is on an SSRI and reports hair changes, clinician attention should go to the serotonergic drug with the stronger pharmacovigilance signal, which is typically the SSRI, not flibanserin.

Patient Counseling Points on Dermatologic Monitoring

Prescribers following up flibanserin patients at the recommended 8-week efficacy reassessment visit should include a brief dermatologic review. The following points support that conversation.

What to Tell Patients Before Starting

Patients should know that the most common side effects are CNS-related (somnolence, dizziness) and that skin reactions are not a primary concern based on the controlled trial data. Alcohol avoidance is the most safety-critical behavioral instruction, not sun protection or hair care changes.

When to Report a Skin Change

Any generalized rash, urticaria, or angioedema warrants immediate contact with the prescribing clinician and should prompt consideration of drug hypersensitivity. Localized, mild flushing after the first few doses often resolves as the patient adjusts to the medication. Hair shedding that begins 2 to 4 months after starting flibanserin should prompt a full workup rather than automatic attribution to the drug.

Reassessment at 8 Weeks

The prescribing information states: "Evaluate the patient after 8 weeks to determine if flibanserin is benefiting the patient. Discontinue flibanserin in patients who do not report improvement" [1]. That 8-week window is also a practical checkpoint to discuss any emerging dermatologic concerns before they are attributed to long-term drug exposure.

Regulatory and Guideline Context

The American College of Obstetricians and Gynecologists (ACOG) addressed HSDD pharmacotherapy in its 2019 practice bulletin on female sexual dysfunction, noting that flibanserin provides modest but statistically significant benefits for desire and distress in premenopausal women [8]. The bulletin does not list dermatologic monitoring as a required component of follow-up care, reinforcing the low priority of that concern relative to CNS and cardiovascular effects.

The North American Menopause Society (NAMS) 2022 position statement on sexual health similarly recommends flibanserin as an option for premenopausal women with HSDD and does not flag hair or skin changes as notable risks in the management algorithm [9]. Both societies emphasize that patient selection (premenopausal status, absence of alcohol use disorder, avoidance of CYP inhibitors) drives safety more than dermatologic monitoring.

Summary of the Evidence on Hair and Skin

The controlled clinical trial program for flibanserin, spanning five Phase 3 studies and more than 11,000 patient-years of exposure, did not identify alopecia or significant primary skin toxicity as treatment-emergent events [1]. Post-marketing surveillance through FAERS has not generated a concentrated hair-loss signal for this drug. Flushing and, rarely, rash appear in the safety profile, but neither is a reason to avoid the drug in appropriately selected patients.

Clinicians who encounter a patient on flibanserin reporting hair changes should pursue a systematic differential workup: thyroid function, ferritin, a complete hormone panel, and a full medication review. The 8-week efficacy assessment mandated by the prescribing information is the appropriate time to capture and document any new dermatologic findings.